BRAIN CANCER

HER2 Breast Cancer

BREAST CANCER

Bladder Cancer

Prostate Cancer

Renal Cell Carcinoma

GENITOURINARY CANCERS

Liquid Biopsies

GENOMIC TESTING

Colorectal Cancer

GIST

Gastric Cancer

GI CANCERS

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

GYNECOLOGIC CANCERS

HEAD & NECK CANCERS

Bone Marrow & Stem Cell Transplant

HEMATOLOGY

CAR T-Cell Therapy

IMMUNOTHERAPY

Chronic Lymphocytic Leukemia

Chronic Myeloid Leukemia

LEUKEMIAS

Biomarker-Driven Lung Cancer

EGFR+ Lung Cancer

MET-Targeted Therapy

Small Cell Lung Cancer

LUNG CANCER

DLBCL

Follicular Lymphoma

Mantle Cell Lymphoma

LYMPHOMAS

MPNs

MULTIPLE MYELOMA

NTRK GENE FUSIONS

SARCOMA

Melanoma

SKIN CANCERS

THYROID CANCERS

NEWS

All News

FDA Briefs

Oncology Icons

Special Reports

The Targeted Pulse

Voices from the Field

CONFERENCES

Conference Coverage

Conference Listing

Data Dialogue with the Oncology Brothers

MEDIA

All Videos

Case-Based Peer Perspectives

Expert Perspective Virtual Tumor Board

Interviews

Investigator Perspectives

Medical World News

Pivotal Practice Views with the Oncology Brothers

Podcasts

Precision Medicine

Speaking Out

PUBLICATIONS

All Publications

Evolving Paradigms

Peers & Perspectives in Oncology

Targeted Therapies in Oncology

CASE-BASED ROUNDTABLE

PARTNERS

RESOURCES

CME/CE

Clinical Trials

Precision Medicine Perspectives

Press Releases

Treatment Resources

SUBSCRIBE

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.

About Us

Advertise

Contact Us

CureToday.com

CancerNetwork.com

OncLive.com

OncNursingNews.com

Do Not Sell My Information

Privacy

Terms & Conditions

Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Facebook

Linkedin

YouTube

Instagram

Featured Clinical Focus

BTK Inhibitors: In-Focus

Bone Marrow & SCT

EGFR-Positive Lung Cancer

Lung Cancer

Multiple Myeloma

Thyroid Cancers

Clinical Focus

Brain Cancer

Breast Cancer

Gastrointestinal Cancer

Genitourinary Cancers

Gynecologic Cancers

Head & Neck Cancers

Hematology

Leukemias

Lymphomas

Sarcoma

Skin Cancers

Spotlight

1rem

View

Key Takeaways From EMERALD: Elacestrant in Patients With Previously Treated ER+, HER2- Metastatic Breast Cancer

Videos

Expert oncologist Virginia Kaklamani, MD, DSc, joins the Oncology Brothers to review data from the EMERALD trial and discuss use of the oral SERD, elacestrant, in patients with ER+, HER2- advanced breast cancer.

The Oncology Brothers are joined by Virginia Kaklamani, MD, DSc, who provides an overview of the EMERALD trial design and use of elacestrant in ER+, HER2- advanced breast cancer. 

Overview of the EMERALD Trial of Elacestrant in ER+, HER2- Advanced Breast Cancer

Expert oncologist Virginia Kaklamani, MD, DSc, joins the Oncology Brothers in highlighting the efficacy and safety data from the EMERALD trial and identifying appropriate use of elacestrant in patients with ER+, HER2- advanced breast cancer. 

EMERALD Trial of Elacestrant in ER+, HER2- Advanced Breast Cancer: Efficacy and Safety Data 

Following their discussion of the EMERALD trial and elacestrant with Virginia Kaklamani, MD, DSc, the Oncology Brothers share clinical implications of the EMERALD trial to practice and look toward the future of ER+, HER2- advanced breast cancer management.

ER+, HER2- Advanced Breast Cancer: Clinical Implications of the EMERALD Trial 

Overview of the EMERALD Trial of Elacestrant in ER+, HER2- Advanced Breast Cancer

EP: 1.Overview of the EMERALD Trial of Elacestrant in ER+, HER2- Advanced Breast Cancer

EP: 2.EMERALD Trial of Elacestrant in ER+, HER2- Advanced Breast Cancer: Efficacy and Safety Data

EP: 3.ER+, HER2- Advanced Breast Cancer: Clinical Implications of the EMERALD Trial